Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Research & Development (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Research & Development for 8 consecutive years, with $13.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 2.05% to $13.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $55.6 million, a 2.5% decrease, with the full-year FY2024 number at $59.6 million, up 11.59% from a year prior.
  • Research & Development was $13.4 million for Q3 2025 at Precision Biosciences, up from $12.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $37.2 million in Q2 2021 to a low of -$8.5 million in Q4 2022.
  • A 5-year average of $16.5 million and a median of $13.6 million in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: tumbled 132.28% in 2022, then skyrocketed 256.71% in 2023.
  • Precision Biosciences' Research & Development stood at $26.5 million in 2021, then crashed by 132.28% to -$8.5 million in 2022, then surged by 256.71% to $13.4 million in 2023, then rose by 18.81% to $15.9 million in 2024, then decreased by 16.06% to $13.4 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Research & Development are $13.4 million (Q3 2025), $12.8 million (Q2 2025), and $13.6 million (Q1 2025).